Lung Cancer

Will graphic images and stronger warnings decrease cigarette smoking?

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

Patients screened with low-dose helical computed tomography (CT) reduced their risk of dying of lung cancer by 20% compared with chest x-ray.

Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study

Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit

Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.

In an effort to draw attention to the dangers of tobacco, the FDA has mandated the inclusion of graphic warnings to cigarette packs and advertisements.

Results of a phase II trial showed that former smokers had significant regression of endobronchial dysplasia when treated with iloprost.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC

New results appear to undercut the longstanding notion that individuals who smoke menthol cigarettes have a higher risk of lung cancer than those who smoke nonmenthol cigarettes

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Patients with node-negative, locally advanced lung tumors who undergo induction chemoradiotherapy appear to survive significantly longer than patients who undergo surgical resection without induction chemoradiotherapy

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

A Canadian study has found that a daily fish oil supplement can thwart chemotherapy-induced muscle and weight loss in lung cancer patients

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Crizotinib was accepted for filing by the FDA and granted Priority Review status

ASTRO has for the first time issued its own extensive guidelines for the use of palliative thoracic radiotherapy in patients with metastatic lung cancer

The chorus of support is growing among oncology experts for routine genetic testing of tumors from patients with advanced non-small cell lung cancer

Negative attitudes toward smokers extend to patients with lung cancer, regardless of whether or not they have ever actually smoked